UK Biobank Study Finds Genetic Factors in Kidney Disease Risk Across Diverse Populations
Researchers from Queen Mary University of London have published findings in a major study identifying previously uncharacterised genetic variants that significantly affect the risk of developing kidney disease across populations of diverse ancestral backgrounds, using data drawn from the UK Biobank and international cohorts to provide one of the most comprehensive trans-ethnic analyses of the genetic architecture of renal disease yet conducted.
Professor Segun Fatumo, who led the research group, noted in commentary published alongside the findings that the historical underrepresentation of people of African ancestry in large genetic studies had left significant gaps in the understanding of how kidney disease risk varies across populations. The new study addressed this gap by including substantial samples from multiple African ancestral groups alongside European, South Asian and East Asian populations, enabling comparative analysis of genetic risk factors that differ in their prevalence and effect size between populations.
The clinical implications are significant. Kidney disease affects approximately one in ten people globally and is a major driver of cardiovascular complications and end-stage renal failure requiring dialysis or transplantation. Identifying individuals at genetically elevated risk before the disease is clinically apparent creates opportunities for earlier intervention through lifestyle modification, pharmacological prevention and more intensive monitoring — interventions that are most effective when implemented before significant kidney damage has occurred.
The research team noted that the variants identified in the study were not uniformly distributed across all populations studied, reinforcing the importance of conducting genetic research in diverse cohorts rather than extrapolating findings from European-ancestry studies to populations with different genetic backgrounds. This principle, of conducting inclusive research that generates findings applicable to global populations rather than a privileged subset, has become an increasing focus of funding bodies and ethics committees in genomic medicine research.
